The RESIST Trials – Superiority of Tipranavir over other Pls

The next antiretroviral agent likely to be approvedis a protease inhibitor (PI) called tipranavir(TPV), which has been specifically developed toaddress the urgent need for new active agents forpeople with limited treatment options due to multidrugresistance. TPV is active against many HIVvariants that have developed resistance to currentlyavailable PIs. In November, the interim results atweek 24 of two identical phase 3 clinical trials ofTPV, called RESIST, were released. RESIST-1, conductedin the USA, Canada and Australia was presentedat the 44th ICAAC, which took place inWashington, while RESIST-2, conducted in Europe,Argentina, Brasil and Mexico, was presented at the7th Drug Therapy Congress, which took place inGlasgow.